Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 7, 2002

View Archived Issues

DepoMed updates clinical status

Sangamo's ZFP technology used to show control of fat cell development

FDA upgrades pregnancy rating for AstraZeneca's Pulmicort Turbuhaler asthma medication

Neurogen and Aventis collaborate to develop CRF1 drugs for depression, anxiety and stress disorders

BioCryst resumes phase III trial of peramivir for the treatment of influenza

IDE filed for Batimastat BiodivYsio stent; enters pivotal phase II trial

Phase II preliminary results of Neurogen's NGD-91-3 for general anxiety disorder

Continuous infusion of Amylin's AC-2993 shown to reduce glucose concentrations over 24 hours

E.U. and U.S. orphan drug designation for Transkaryotic Therapies' Hunter's syndrome treatment

Shire and HydroMed realign histrelin agreement

Oxis Turbuhaler receives pediatric license in the EU

HMR-3270, a new promising antifungal candin

Antirhinoviral compounds reported by Essential Therapeutics

Indole and chromene derivatives with potent antibacterial activity patented by Roche

Nippon Chemiphar designs new PPARdelta receptor agonists

Novel bacterial RNA polymerase inhibitors patented by Tularik

Cor Therapeutics reports new series of platelet ADP receptor inhibitors

GSK-3 inhibitors reported to be useful for Alzheimer's disease

CDK inhibitors useful as anticancer agents reported by LG Chem

Antiviral pyrimidine nucleoside analogues disclosed by university researchers

Motilin antagonists disclosed at Ortho-McNeil

Novel lantibiotics reported at ICAAC

GSQ-5028 selected to demonstrate the mechanism of action of HARPs

CP-642959: a new oxime ether ketolide with promising activity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...